SCHEMBL29696388

SCHEMBL29696388

NC(=O)c1nc(-c2cn[nH]n2)nc2cc[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.42
MAPK1 P28482 1/20 0.38
METAP2 P50579 7/20 0.36
KDM4E B2RXH2 1/20 0.35
KDM4A O75164 1/20 0.35
KDM5C P41229 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35
KDM3A Q9Y4C1 1/20 0.35
IDO1 P14902 5/20 0.34
KEAP1 Q14145 1/20 0.34
SIRT3 Q9NTG7 1/20 0.34
JAK2 O60674 1/20 0.34
ROCK2 O75116 1/20 0.34
PAK4 O96013 1/20 0.34
PIM1 P11309 1/20 0.34
KDR P35968 1/20 0.34
GSK3B P49841 1/20 0.34
AURKB Q96GD4 1/20 0.34
CD38 P28907 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22936262 0.77 CD38 (0.47) JAK2CD38
SCHEMBL300814 0.75 IKBKB (0.47) MAPK1CD38PDPK1IKBKBCHUK
SCHEMBL29696570 0.71 PDPK1 (0.40) MAPK1KDRCD38PDPK1IKBKB
SCHEMBL22936261 0.71 CD38 (0.69) CD38
SCHEMBL28741959 0.66 METAP2 (0.61) LRRK2MAPK1METAP2IDO1KEAP1
SCHEMBL29626795 0.65 METAP2 (0.63) METAP2KDM4EKDM4AKDM5CKDM4C
SCHEMBL28741907 0.65 METAP2 (0.63) METAP2KDM4EKDM4AKDM5CKDM4C
SCHEMBL29494927 0.64 DYRK1A (0.50) MAPK1PDPK1IKBKBCHUK
SCHEMBL29495219 0.63 CD38 (0.55) LRRK2KEAP1CD38LATS1
SCHEMBL29882414 0.60 PDPK1 (0.45) LRRK2KEAP1JAK2PAK4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP claimed
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP disclosed